COSTEM 2022 | The role of molecular markers in patient selection for transplantation in myelofibrosis
Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the role of mutation panels in selecting patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) for patients with myelofibrosis (MF). MF is a heterogenous condition, where patients have variable lifespans. Existing molecular markers such as p53 and ASCL1 alone are insufficient for patient selection and Prof. Kröger additionally highlights how the presence of high-risk markers such as ECH2, IDH1 ASXL1, and p53 increase the risk of mortality. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
